HistoSonics, Inc.

Innovative treatment option provides hope for those otherwise unable to receive liver cancer treatment NEWPORT BEACH, Calif., Oct. 14, 2024 /PRNewswire/ -- Hoag announced today a new technology using ultrasound energy to precisely destroy liver tumors in a single outpatient visit. HistoSonics Edison Histotripsy System is a precise, non-invasive cancer treatment option and the only FDA-approved therapy of its kind for treating liver tumors. As an alternative to radiation therapy, Histotripsy uses targeted ultrasound waves to wipe out cancer cells. The sound waves produce mini bubbles within the tumor, creating pressure to eradicate unhealthy cells, all while keeping surrounding liver structures and healthy tissue intact. This FDA-approved treatment is performed by Hoag interventional radiologists and can coincide with chemotherapy and other treatment methods. Histotripsy has little to no side effects and patients usually go home the same day. Hoag's investment in Histotripsy underscores the hospital's commitment to innovation in the name of patient care. "We are excited to offer the latest advancements in the battle against cancer. Hoag is proud to be among a select few centers nationwide to offer patients access to the best treatments and most advanced technologies available today. This includes Histotripsy, a newly approved therapy which will revolutionize the treatment of cancer utilizing a non-invasive method to destroy cancer in the liver without a single incision," said Trushar Patel, M.D., Chief of Interventional Radiology and Interventional Oncology at Hoag Hospital. Hoag Digestive Health Institute and Hoag Family Cancer Institute clinicians work together to provide liver cancer patients with the very latest treatment options, resulting in better outcomes. "The treatment for patients with cancer in the liver can be complex and nuanced. We have a multidisciplinary team of fellowship-trained specialists in hepatology, liver surgery, advanced endoscopy, diagnostic and interventional radiology along with our care counselor and dietician, who will guide you through your entire care journey," said Kenneth J. Chang, M.D., Executive Medical Director of the Digestive Health Institute at Hoag. "The combined expertise of our Digestive Health and Cancer Institutes gives patients access to the most advanced diagnostics, individualized therapies and treatment options as well as groundbreaking clinical trials." This revolutionary technology is already showing promising results. "Our early experience indicates that patients with any cancer type with liver metastasis can greatly benefit from this non-invasive, outpatient cancer-fighting procedure," said Tara Seery, M.D., medical oncologist at Hoag. "Histotripsy allows us to offer renewed hope to our patients and their loved ones, especially for those who would otherwise not qualify for surgery." For more information, visit hoag.org/histotripsy. ABOUT HOAG Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 16 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women's health, and orthopedics through Hoag's affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org. SOURCE Hoag WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The proceeds will also help launch HistoSonics' BOOMBOX study, to evaluate Edison’s use against liver cancer among multidisciplinary healthcare providers. A separate study is exploring its capability in kidney cancer. After collecting a de novo clearance from the FDA last fall for its ultrasound-powered liver cancer treatment, HistoSonics has raised $102 million in funds to turn up the volume on its commercial efforts.The company’s Edison system uses the vibrations from focused pulses of sound waves to create bubbles of gas within a tumor—beaming enough energy to ultimately liquify and destroy the target at the cellular level while sparing the surrounding tissue.The former Fierce 15 winner’s series D round was led by Alpha Wave Ventures and was joined by Amzak Health, HealthQuest Capital, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, Yonjin Venture, and the State of Wisconsin’s investment board among others. “Histotripsy is a paradigm-changing treatment option for patients who want a non-invasive approach to target and destroy tumors without the need for needles or incisions,” HistoSonics President and CEO Mike Blue said in a statement.“We’re thrilled to announce this top-tier investor syndicate led by Alpha Wave, which reinforces the confidence in our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types,” Blue added.“This funding will accelerate key projects designed to enhance core technical capabilities impacting current and future platforms, and support collaboration with physicians and researchers studying innovative ways to use histotripsy’s unique mechanism of action to improve patient outcomes.” The proceeds will also help launch the company’s BOOMBOX master study, which will evaluate Edison’s use against liver cancer among multidisciplinary healthcare providers. It also plans to double the size of its Minneapolis, Minnesota-area headquarters, according to a report from the Star Tribune.Earlier this year, HistoSonics reported that its first patients with liver cancer were treated at the University of Rochester Medical Center in New York and at the Cleveland Clinic, following its FDA green light.Shortly thereafter, the company said it treated its first patient with kidney cancer through an ongoing clinical trial, at AdventHealth Celebration in Florida.“This groundbreaking technology has the potential to transform the treatment landscape for a variety of challenging clinical conditions, offering patients improved outcomes and recovery times,” said Chris Dimitropoulos, managing director of healthcare investments at Alpha Wave Global, who will also join HistoSonics’ board of directors. “The level of adoption we’ve seen from leading hospital centers across the country and overseas highlights the huge unmet medical need.”

Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024. Ms. Rogers, an accomplished innovator and entrepreneur, brings over 30 years of experience leading high-growth health technology companies to Medicines360. She previously served as Medicines360’s Chief Operating Officer (COO) from 2010 to 2012, and on the Board as a Director from 2012 to 2014. She returns at another transformational moment in the company’s development, as Medicines360 rapidly extends its reach to serve more women in more ways across the globe. “Medicines360 has demonstrated considerable impact, helping over 1.5 million women to date, driven by its mission to improve equitable health outcomes,” said Ms. Rogers. “I’m honored to return to the organization at this pivotal growth stage and accelerate the timeline from health innovation to access for all women.” Ms. Rogers is a renowned medical technology industry trailblazer and entrepreneur. She served as President and CEO of Silk Road Medical from 2012 to 2023, where she successfully navigated the organization from early venture funding and clinical trials to a successful Initial Public Offering (IPO) in 2019, while simultaneously cultivating a mission-driven company culture. Prior to Medicines360 and Silk Road Medical, Ms. Rogers co-founded two medical device companies, and is a named inventor on over 25 U.S. medical technology patents. Ms. Rogers spent over 12 years in sales and marketing roles at Boston Scientific, a global medical technology company. “We are thrilled to welcome Erica Rogers to our Board of Directors. Ms. Rogers’ extensive experience and leadership in navigating the complex drug and device commercialization landscape will be invaluable to our organization,” said Medicines360 CEO Andrea Olariu. “She will be a key advisor to us as we expand our product portfolio offerings to address additional unmet needs in the area of women’s health.” Ms. Rogers currently sits on the Board of Directors at HistoSonics and Sight Sciences, and serves as an Investment Advisor to Venture Investors. She previously sat on the Board of Directors of Lucira Health and served as an Advisor to Alydia Health, which was acquired by Organon in 2021. In addition, she has been a strong advocate for women in science and engineering executive roles, serving as a leader in AdvaMed’s Women’s Executive Network, among other leadership roles. She received the MedTech MVP Award in 2023, EY Entrepreneur of the Year award in 2020 and the Forbes 50 over 50 award in 2022. About Medicines360 Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org. Contacts: Anna BrittWaxman Strategies540-808-6963anna@waxmanstrategies.com Heidi GlasserMedicines360415-951-8700hglasser@medicines360.org A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c2c2b5-e980-4dd4-84b2-515c0d8d58c3